SIM2: A Potential Drug Target for PDGF-BB and Cell Signaling (G6493)

Target Name: SIM2

NCBI ID: G6493

SIM2

SIM2: A Potential Drug Target for PDGF-BB and Cell Signaling

SIM2 (SIM2 variant SIM2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the SIM2 family of proteins, which are known for their role in intracellular signaling. SIM2 has been shown to play a role in a variety of biological processes, including cell signaling, tissue repair, and inflammation. As a result, SIM2 has generated a lot of interest as a potential drug target or biomarker.

SIM2 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is a member of the SIM2 family of proteins, which are characterized by the presence of a specific domain called the catalytic histidine residue (HIR). This domain is known for its ability to catalyze the hydrolysis of histidine residues, which is a key step in the regulation of intracellular signaling. SIM2 is also known for its ability to interact with several other proteins, including the transcription factor p53.

SIM2 has been shown to play a role in a variety of biological processes. For example, SIM2 has been shown to be involved in the regulation of cell signaling by the protein PDGF-BB. PDGF-BB is a potent growth factor that is involved in the development and maintenance of tissues, including the brain. SIM2 has been shown to interact with PDGF-BB and to regulate its activity. This suggests that SIM2 may be a good target for drugs that are designed to inhibit PDGF-BB signaling.

In addition to its role in cell signaling, SIM2 has also been shown to be involved in the regulation of tissue repair and inflammation. For example, SIM2 has been shown to be involved in the regulation of cell death in response to tissue damage. When tissues are damaged, SIM2 helps to ensure that cells are able to repair the damage and survive, which is essential for the maintenance of tissue homeostasis. SIM2 has also been shown to be involved in the regulation of inflammation, as it has been shown to play a role in the regulation of the immune response.

SIM2 has also been shown to have potential as a drug target in cancer. For example, SIM2 has been shown to be involved in the regulation of cell proliferation and has been shown to be a potential therapeutic target for cancer. SIM2 has been shown to interact with the protein PD-L1, which is a protein that is overexpressed in many types of cancer. This suggests that SIM2 may be a good target for drugs that are designed to inhibit PD-L1 signaling.

SIM2 has also been shown to be involved in the regulation of the blood-brain barrier. The blood-brain barrier is a barrier that separates the brain from the bloodstream, and it is designed to protect the brain from harmful substances that could enter the brain. SIM2 has been shown to play a role in the regulation of the blood-brain barrier, as it has been shown to interact with the protein tight junction protein (TJP). This suggests that SIM2 may be a good target for drugs that are designed to inhibit TJP signaling.

In conclusion, SIM2 is a protein that has been shown to play a role in a variety of biological processes, including cell signaling, tissue repair, and inflammation. As a result, SIM2 has generated a lot of interest as a potential drug target or biomarker. Further research is needed to fully understand the role of SIM2 in these processes and to determine its potential as a therapeutic target.

Protein Name: SIM BHLH Transcription Factor 2

Functions: Transcription factor that may be a master gene of CNS development in cooperation with Arnt. It may have pleiotropic effects in the tissues expressed during development

The "SIM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets